Long-Term Follow-Up of Y-Ibritumomab Tiuxetan, Fludarabine, and Total Body Irradiation-Based Nonmyeloablative Allogeneic Transplant Conditioning for Persistent High-Risk B Cell Lymphoma.

Biol Blood Marrow Transplant 2018 11 3;24(11):2211-2215. Epub 2018 Jul 3.

Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, Washington; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. Electronic address:

Nonmyeloablative allogeneic hematopoietic cell transplantation (HCT) can provide prolonged remissions in patients with advanced B cell lymphoma (B-NHL) via the graft-versus-lymphoma effect, although inferior results are seen in patients with chemoresistant, bulky, or aggressive disease. Radioimmunotherapy can safely induce responses in B-NHL with minimal nonhematologic toxicity. Initial results of Y-ibritumomab tiuxetan-based allografting demonstrated early safety and disease control in nonremission patients but with short follow-up. Here we report the long-term outcomes of patients treated on this study with specific emphasis on patients achieving early remissions. Eleven of 40 patients were alive at a median follow-up of 9 years (range, 5.3 to 10.2). Fourteen (35%) deaths were due to disease progression and 14 (35%) deaths to complications from HCT. One patient died of a Merkel cell carcinoma. The 5-year overall and progression-free survival for patients with indolent B-NHL was 40% and 27.5%, respectively. None of the patients with diffuse large B cell lymphoma was a long-term disease-free survivor regardless of early remission status. Y-ibritumomab tiuxetan-based allografting represents a viable option in patients with indolent histologies. Improved strategies are needed for aggressive B-NHL. The original trial was registered at www.clinicaltrials.gov as NCT00119392.

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10838791183038
Publisher Site
http://dx.doi.org/10.1016/j.bbmt.2018.06.033DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6251312PMC
November 2018
43 Reads

Publication Analysis

Top Keywords

cell lymphoma
12
patients
9
nonmyeloablative allogeneic
8
patients indolent
8
35% deaths
8
tiuxetan-based allografting
8
y-ibritumomab tiuxetan-based
8
cell
5
eleven patients
4
patients alive
4
median follow-up
4
follow-up 9 years
4
alive median
4
102 fourteen
4
disease progression
4
progression 35%
4
deaths complications
4
deaths disease
4
fourteen 35%
4
range 102
4

Similar Publications